Cargando…

MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer

Brian metastasis, which is diagnosed in 30% of triple-negative breast cancer (TNBC) patients with metastasis, causes poor survival outcomes. Growing evidence has characterized miRNAs involving in breast cancer brain metastasis; however, currently, there is a lack of prognostic plasma-based indicator...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jhih-Kai, Lin, Cheng-Han, Kuo, Yao-Lung, Ger, Luo-Ping, Cheng, Hui-Chuan, Yao, Yun-Chin, Hsiao, Michael, Lu, Pei-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932919/
https://www.ncbi.nlm.nih.gov/pubmed/33536579
http://dx.doi.org/10.1038/s41388-021-01654-3
Descripción
Sumario:Brian metastasis, which is diagnosed in 30% of triple-negative breast cancer (TNBC) patients with metastasis, causes poor survival outcomes. Growing evidence has characterized miRNAs involving in breast cancer brain metastasis; however, currently, there is a lack of prognostic plasma-based indicator for brain metastasis. In this study, high level of miR-211 can act as brain metastatic prognostic marker in vivo. High miR-211 drives early and specific brain colonization through enhancing trans-blood–brain barrier (BBB) migration, BBB adherence, and stemness properties of tumor cells and causes poor survival in vivo. SOX11 and NGN2 are the downstream targets of miR-211 and negatively regulate miR-211-mediated TNBC brain metastasis in vitro and in vivo. Most importantly, high miR-211 is correlated with poor survival and brain metastasis in TNBC patients. Our findings suggest that miR-211 may be used as an indicator for TNBC brain metastasis.